A revolutionary new cancer treatment – and the blue-chip stock set to benefit

A new kind of cancer therapy could make a big difference to survival rates - and transform the fortunes of one big UK drugs company. Matthew Partridge explains.


Scientists are developing a new kind of cancer therapy

A revolution in medicine is picking up steam a revolution that could transform the prospects of many cancer patients.

For years there have been three main ways to fight cancer: surgery, radiation and chemotherapy. They all boil down to destroying the cancer cells, either by cutting them out, burning them or poisoning them.

In many cases this works, but sadly not for everyone.

The good news is that scientists are now developing a new kind of cancer therapy, one that could make a big difference to survival rates.

And it could also transform the fortunes of one big UK drugs company.

Using the body's own immune system to fight cancer

The first person to actively use this knowledge to fight the disease was William Coley, a New York surgeon and bone cancer specialist. After one of his first patients died of cancer, he searched for treatments that could improve survival rates. He observed that those who developed infections from surgery were, paradoxically, more likely to survive afterwards.

Taking a gamble, he injected streptococcus bacteria into a patient who had cancer. The patient's malignant tumour shrank. Coley went on to use the method (known as Coley's Toxins') on over 1,000 patients until his death in 1937.

Yet his breakthrough was ignored by most of the medical profession. Doctors of the time used case studies rather than proper trials. This made it hard to gauge survival rates for particular therapies. And modern trials of Coley's Toxins have produced mixed results compared to modern therapies, though the treatment may have some use in advanced cases.

Meanwhile, the development of radiation therapy and early forms of chemotherapy which seemed to provide more immediate benefits also reduced interest in Coley's techniques. Their use finally died out in the 1950s.

Three new approaches to attacking cancer

Basically, there are three distinct strands to this, each of which has produced useful treatments.

The simplest idea is to develop antibodies that can stimulate the immune system to identify, and then then attack, cancer cells. Rituximab, the first antibody targeting blood cancer, was approved in 1998, and is now a standard treatment. Additional antibodies have been released, and several more are in development.

A similar approach which is gaining traction is based on evidence that cancer cells produce molecules (known as PD-1, PD-L1 and PD-L2) that act like brakes on the immune system and prevent them from being destroyed. Targeting and turning off these molecules can allow the body's defences to do their work.

An even more radical approach is to attempt to re-engineer a person's immune system altogether. This involves taking white blood cells from the patient's body and modifying them using genetic engineering, so that they can more effectively deal with the cancer when they're back in the body.

Make no mistake these are all high-risk approaches. Trying to find drugs that will allow the immune system to fight cancer is a case of trial and error. Individual cancers vary from person to person. Many people may not receive any benefit at all from these approaches.

And a stimulated immune system can spin out of control, causing auto-immune diseases that attack healthy tissue or even organs. Patients may also develop antibodies that target or interfere with cancer drugs they are using.

As a result, these treatments have mainly been tested on people with advanced cancers that are otherwise untreatable.

However, despite all the caveats, the results for this group have been promising. For instance, one PD-1 inhibitor (ipilimumab) has shrunk the tumours of more than half of people with a sub-type of an incurable lung cancer, and dramatically boosted their survival rates.

Pfizer wasn't just looking to dodge taxes when it bid for Astra




In 2011 it bought the rights to Tremelimumab, which inhibits molecules that protect cancer cells, from Pfizer. When Pfizer tried to buy Astra earlier this year, it wasn't just for the tax breaks (attractive though they were). It was partly to get the rights to Tremelimumab back.

In an effort to increase the speed of drug development, Astra has just signed partnership deals with Japanese firm Kyowa Hakko Kirin and Advaxis, which specialises in immunotherapies.

At 17 times 2015 earnings, AstraZeneca is by no means cheap. However, its strong pipeline should allow it to generate enough cash to maintain its dividend of 3.8%.

There are some smaller stocks in this field which, while higher risk, are certainly worth investigating. My colleague Tom Bulford covers one of these and lots of other exciting medical breakthroughs in his Red Hot Biotech Alert newsletter. If you'd like to know more about subscribing to his in-depth research, call our customer services team on 020 7633 3602.

Red Hot Biotech Alert is a regulated product issued by Fleet Street Publications Ltd. Your capital is at risk when you invest in shares, never risk more than you can afford to lose. Forecasts are not a reliable indicator of future results. Please seek independent financial advice if necessary. Fleet Street Publications Ltd. 0207 633 3600.

Our recommended articles for today

The one word I'm sick of hearing

Investors should head for the bunkers


Tensions are rising between the West and Russia. This will have a serious impact on the economy. John Stepek explains how you can protect your investments.

On this day in history

1 August 1981: MTV goes on air


Beyond US tech stocks: three global stars to buy now
Share tips

Beyond US tech stocks: three global stars to buy now

There is much to like about the US tech giants, says professional investor Alec Cutler of Orbis Investments highlights. But there are many other excel…
1 May 2021
Three winners of the long-term biotech boom
Share tips

Three winners of the long-term biotech boom

Professional investor Marek Poszepcynski of the International Biotechnology Trust picks three biotech stocks with good pipelines, strong management te…
22 Mar 2021
The unscientific criticism of AstraZeneca could do lasting damage
Biotech stocks

The unscientific criticism of AstraZeneca could do lasting damage

Several European countries have suspended their use of AstraZeneca's Covid vaccine – for no good scientific reason. Matthew Partridge reports.
18 Mar 2021
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Feb 2021

Most Popular

What is hyperinflation and could it happen here?

What is hyperinflation and could it happen here?

The Bank of England has been accused of the kind of money-printing that could lead to Zimbabwe-style hyperinflation. But that's very unlikely to happe…
4 May 2021
Copper has hit a ten-year high, but this could just be the start of a huge bull market
Industrial metals

Copper has hit a ten-year high, but this could just be the start of a huge bull market

The price of copper is at its highest for ten years. But supply constraints and a massive rise in demand mean it’s not going to stop there, says Domin…
5 May 2021
Micro-cap stocks: how to get huge returns from tiny firms
Small cap stocks

Micro-cap stocks: how to get huge returns from tiny firms

Micro-cap stocks are often overlooked, but the British market has plenty of them and their potential is massive. Max King picks the best two investmen…
3 May 2021